Skip to main content Accessibility help
×
Hostname: page-component-78c5997874-ndw9j Total loading time: 0 Render date: 2024-11-16T18:21:39.271Z Has data issue: false hasContentIssue false
This chapter is part of a book that is no longer available to purchase from Cambridge Core

14 - Biomolecular Engineering II: Engineering of Immunity

from PART 3 - BIOMEDICAL ENGINEERING

W. Mark Saltzman
Affiliation:
Yale University, Connecticut
Get access

Summary

LEARNING OBJECTIVES

After reading this chapter, you should:

  • Understand the role of vaccines in the prevention of disease.

  • Understand the role of antibodies (Abs) in the immune system, and some of the ways that Abs can be used to prevent disease in humans.

  • Understand the basic elements of Ab structure, and the difference in chemical structure between Ab classes.

  • Understand the difference between monoclonal and polyclonal Abs.

  • Understand how monoclonal antibodies (mAbs) are manufactured.

  • Understand some of the basic approaches for vaccine development.

Prelude

The previous chapter introduced three of the major subjects of interest in biomolecular engineering: drug delivery, nanobiotechnology, and tissue engineering. This chapter focuses on additional applications of biomolecular engineering, particularly approaches for enhancing the function of the immune system. The most familiar application of biomedical engineering (BME) in immunology is the development of vaccines.

The development of vaccines that are both safe and effective has been one of the great achievements of modern medicine. Because of an effective vaccine, smallpox—a frequently fatal disease that claimed thousands of lives in previous centuries—has been eradicated, or eliminated as a natural infectious agent. Other severe infectious diseases, such as polio and influenza, are now in control in most countries of the world. There are, however, many diseases that have proven to be difficult for vaccine makers. Acquired immune deficiency syndrome (AIDS), which is caused by infection with human immunodeficiency virus (HIV), has killed millions of people worldwide (Figure 14.1), and there is still no effective vaccine available.

Type
Chapter
Information
Biomedical Engineering
Bridging Medicine and Technology
, pp. 507 - 536
Publisher: Cambridge University Press
Print publication year: 2009

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Kohler, G, Milstein, C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature. 1975;256:495–497.CrossRefGoogle ScholarPubMed
Liu, XY, Pop, LM, Vitetta, ES. Engineering therapeutic monoclonal antibodies. Immunol Rev. 2008;222:9–27.CrossRefGoogle ScholarPubMed
Saltzman, WM, Shen, H, Brandsma, JL, eds. DNA Vaccines. New York: Humana Press; 2006.

Save book to Kindle

To save this book to your Kindle, first ensure [email protected] is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×